Agenda

Friday, 17th March, 2023

Welcome Reception 6:30pm

Saturday 18th March, 2023; DAY 1

Introduction: Gareth Morgan & Keith Stewart 9:00am-9:10am

Overview lecture I; Gareth Morgan 9:10am-9:30am 

Biology of HR

Session I: Genomics 2022 9:30am -10.50am

Chairs: Francesco Maura and Leif Bergsagel

The genomics of and definition of SMM; Leif Bergsagel
Utility of mutational and copy number signatures as prognostic factors; Kylee MacLachlan
Time of origin and evolutionary trajectories to MM; Francesco Maura
Molecular definitions of High-risk MM and their utility for trial entry; Jill Corre
Clonal substructure and drivers of MM relapse; Niels Weinhold

Panel Discussion: What’s next in Genomics 10:20 am-10:50am

Coffee Break 10:50am-11:10am

Session II: Overview lecture II;  Irene Ghobrial 11:10am-11:30am

Resistance mechanisms mediated via the Microenvironment

Chairs: Irene Ghobrial and Niels Weinhold 11:30am – 12:50pm

Therapy resistance and utility of targeting apoptosis in MM; Lawrence Boise
Microenvironment-mediated resistance to treatment; Madhav Dhodapkar
Revlimid resistance as a clinical and biological entity; Charlotte Pawlyn
Sequencing and IMiD resistance; Sarah Gooding
Resistance and side effects of TCE-bispecifics; Samir Parekh
Immune dependent mechanisms leading to resistance to T cell Engagers in Myeloma; Paola Neri

Panel Discussion: Overcoming Drug resistance 12:30pm-12:50pm

LUNCH 12:50pm -1:50pm

Session III: Novel targets 1.

Overview lecture III; Jesus San-Miguel 1:50pm-2:15pm

How to incorporate MRD in clinical trials and routine practice

Chairs: Charlotte Pawlyn and María-Victoria Mateos 2:15pm – 3:35pm

Using the Vk*MYC mouse model to understand early stages of myelomagenesis; Marta Chesi
Pre-clinical MM models for predicting clinical immunotherapy outcomes; José Ángel Martínez Climent
Utility of Epigenetic analysis of MM plasma cells; Felipe Prosper
Novel risk scores and endpoints for trials in SMM trials; Maria-Victoria Mateos
• The biology of remission and of a high-risk microenvironment; Bruno Paiva

Panel Discussion: Future strategies for myeloma management 3:05pm-3:35pm

Break: 3:35pm -3:50pm

Overview lecture IV; Keith Stewart 3:50pm – 4:10pm

The future of MM therapy

Session IV: The future of myeloma therapy: 4:10pm-5:15pm
Chairs: Rafael Fonseca and George Mulligan

The clinical utility of frailty in clinical trial designs; Claudia Stege
Translational studies associated with current and planned trials of MM in the USA; Brian Walker
Translational studies associated with current and planned trials of MM in Europe; Martin Kortüm
Recent developments from trials of isatuximab; Fredrik Schjesvold

Group Discussion: Response and MRD directed therapy and in the clinic 4:50pm – 5:15pm

Wrap up and end Day1 5:15pm-5:20pm

Day 2 Sunday 19th March, 2023

Session V: Novel Targets 2:                    09:00am-10:20am

Chairs: Elena Zamagni and Paola Neri

Utilising imaging modalities as endpoints in clinical trials; Elena Zamagni
The role of Iberdomide and Mezigomide in 2023 and beyond; Nizar Bahlis
Other therapeutic vulnerabilities (Modakafusp, PDCs, BCL2 inhibitors…); Enrique Ocio
Innovative CAR-T designs and targets; Carlos Fernández de Larrea

Panel Discussion: Developing novel targets for the clinic. 09:50am-10:10am

Coffee Break 10:10am-10:30am

Session VI: Debate curing MM and how to achieve it 10:30am-11:25am

Chairs: Gareth Morgan

European Perspective; Pieter Sonneveld
US Perspective; Sagar Lonial

Panel Discussion 10:55am-11:25am

Overview Lecture V; Maria-Victoria Mateos 11:25am-11:45am

T-cell engaging therapy

Session VII: T-Cell Engagers: 11:45am-1:15pm

Chairs: Maria-Victoria Mateos and Eric Smith

Update session on bispecifics and CAR-T cell therapy

Teclistamab; Suzanne Trudel
Elranatamab; Nizar Bahlis
Ide-cel; Yi Lin
Cilta-cel; Adam Cohen
Talquetamab; Paula Rodriguez
GPRC5D CAR T-cells; Eric Smith

Panel Discussion – Optimizing the use of Bi-specifics and CAR-T in the clinic 12:45pm-1:15pm

Summary and close of iwMyeloma 2023 1:15-1:30pm
Gareth Morgan, Keith Stewart

iwMyeloma Scientific Committee:

Keith Stewart (Co-Chair) USA, Gareth Morgan (Co-Chair) USA
Kenneth Anderson USA, Leif Bergsagel USA, Irene Ghobrial USA, Ola Langdren USA, Sagar Lonial USA, Maria-Victoria Mateos Spain, Jesus San-Miguel Spain, Pieter Sonneveld NL